UKVIA welcomes new evidence that vaping is significantly more effective than NRT for quitting smoking

By October 16, 2020UKVIA News

Study backs up recent findings by Public Health England and the National Institute of Health Research and Cancer Research UK

 

The UK Vaping Industry Association has welcomed new research that has found that vaping is 70% more effective in helping smokers to quit cigarettes than nicotine replacement therapy (NRT), such as patches and gum.

The study undertaken by Cochrane, which reviewed 50 studies across the world, with more than 12,000 participants, also showed that an additional 60 % could potentially quit smoking with nicotine containing electronic cigarettes. In addition, the review found that “there was no evidence that people using nicotine containing e-cigarettes reported more serious health problems than people using nicotine-free e-cigarettes, NRT or no therapy at all.”

John Dunne, director general at the UK Vaping Industry Association (UKVIA), welcomed the findings:

“They add to a growing catalogue of evidence supporting vaping’s role in smoking cessation. Quitting cigarettes can be difficult, which is why adult smokers must have access to the most effective tools available.

“This review underlines the enormous potential vaping holds for public health, particularly as the Government aims for a smoke-free UK by the end of the decade. We call on all stakeholders, from policy makers to health professionals, to seize the opportunity which vaping represents, and to give smokers the best chance of quitting successfully.”

Dunne added: “This review builds on research by the National Institute of Health Research and Cancer Research UK which showed that vaping was far more effective than nicotine replacement therapy products and Public Health England’s vaping evidence review this year highlighted data from stop smoking services in England that suggested when a vaping product is used in a quit attempt, either alone or with licensed medication, success rates are comparable to, if not higher that licensed medication alone.”

[ENDS]

For further details and press enquiries please contact Stuart Edgar on 07769297918 or at stuart.edgar@jbp.co.uk